{"id":"W2139204856","doi":"10.1056/nejmoa0902533","title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1007,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"UCB Pharma; EMD Serono; Genentech; Multiple Sclerosis Society of Canada; Sanofi; Bayer HealthCare; Vertex Pharmaceuticals; Teva Pharmaceutical Industries; Acorda Therapeutics; Ironwood Pharmaceuticals, Incorporated; Biogen; Pfizer","keywords":"Cladribine; Medicine; Multiple sclerosis; Placebo; Relapsing remitting; Oral administration; Clinical trial; Internal medicine; Oncology; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003772823,0.0002337988,0.00168112,0.0004349963,0.00009612261,0.000009803497,0.0002012575,0.0001375411,0.0002041998],"category_scores_gemma":[0.02042325,0.0001378885,0.0003550503,0.0002274084,0.0002972727,0.0001075044,0.00004226726,0.0008193832,0.000001438028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004689693,"about_ca_system_score_gemma":0.0003578412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009992239,"about_ca_topic_score_gemma":0.0001784941,"domain_scores_codex":[0.996963,0.0001291849,0.001319647,0.0001918872,0.001017699,0.0003785655],"domain_scores_gemma":[0.9950765,0.002383016,0.0007867759,0.000293848,0.0009587364,0.0005011691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6002896,0.0003125661,0.001659589,0.00008608386,0.0005094652,0.00001762013,0.0006114611,0.000007388345,0.2823187,0.0000305827,0.01598932,0.09816759],"study_design_scores_gemma":[0.9603471,0.00879534,0.002310538,0.001010468,0.0005650077,0.0001324024,0.0001703922,0.0007120167,0.003344737,0.000120547,0.02238276,0.0001087092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975027,0.000768534,0.001699362,0.01650619,0.002570271,0.002571878,0.000008049233,0.0000195666,0.0008291011],"genre_scores_gemma":[0.9818141,0.000871893,0.00940719,0.0001404653,0.006987143,0.0000295795,0.000006247411,0.00003431615,0.0007090286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3600574,"threshold_uncertainty_score":0.9878281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08532440594402674,"score_gpt":0.3402950320820509,"score_spread":0.2549706261380242,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}